The Ocular Disorders: Rising Therapeutics, Technologies, and Devices – Overview report begins with outlining Age-related macular degeneration (both wet and dry) and delving into Anti-VEGF therapies in chapter 2. Further providing substantial weight to this report, several companies were interviewed on their approach to targeting wet and dry AMD, their strategies for seeking alternative therapeutic options, and the hardships they have encountered in their research and product execution.
Ocular Disorders: Rising Therapeutics, Technologies, and Devices – Overview report spreads across 208 pages strengthened with figures and tables is available at:
This report provides an exclusive interviews from four companies (Oraya Therapeutics, VisionCare Ophthalmic Technologies, Omeros, and Kala Pharmaceuticals) providing details of their products. It discusses both invasive and noninvasive procedures, along with current treatment options and how they relate to rising therapies. It provides demographic survey and analysis of researchers working in ocular disorders including promising therapeutic options, targets of interest, and challenges encountered. The report also features clinical trials and pipeline data for over 250 companies. In the end the report includes over 200 company and institution profiles.
This “Ocular Disorders: Rising Therapeutics, Technologies, and Devices” report covers several companies and their approach to targeting ocular diseases including wet and dry age-related macular degeneration (AMD) while also providing alternative therapeutic options for various ocular complications. In an interview with several companies including Oraya Therapeutics, VisionCare Ophthalmic Technologies, Omeros, and Kala Pharmaceuticals, representatives mentioned several technologies and devices in development to improve the current line of therapeutics.
Both invasive and noninvasive procedures are discussed, along with current treatment options and how they relate to rising therapies. Specific highlights of this report include extensive research, company backgrounds, challenges, and validation techniques for therapeutic applications offered by the participating companies. These techniques include: Radiation therapy, Implantable telescope technology, PharmacoSurgery and Mucosal penetrating products.
Purchase a Single User License Copy of “Ocular Disorders: Rising Therapeutics, Technologies, and Devices – Overview” Report at http://www.reportsnreports.com/purchase.aspx?name=274702 for US $1995.
Also available are complementary interviews with company representatives at the end of each section.
The interviewees include: President and CEO of Oraya Therapeutics, Marketing Director of VisionCare Ophthalmic Technologies, Chairman and CEO of Omeros and CMO of Kala Pharmaceuticals.
Also included in this report is a demographic survey of researchers working in ocular disorders. Some of the concepts include ocular areas of research, promising therapeutic options, targets of interest, and challenges encountered.
Company Profiled are: 13therapeutics, Inc., 2C Tech Corporation, Inc., AbbVie Inc., Abdi Ìbrahim Ìlac Sanayi ve Tic A.S. (Abdi Ibrahim), AC Immune SA, ACADIA Pharmaceuticals, Aciex Therapeutics, Inc., Aciont Inc., Acorn Biomedical, Inc., Actavis hf., Acucela Inc., Adamed Sp. z o.o., Adenovir Pharma AB, AdeTherapeutics Inc., Allergan S.A.U., Altacor, Altheos, Inc., Amakem Therapeutics NV, AmorChem L.P., AngioLab, Inc., Ångstrom Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., Apitope International NV, Applied Genetic Technologies Corp. (AGTC), BioMotiv LLC, Bionure, Biophytis, Bloomage BioTechnology Corporation Limited, BluBio (Yantai) Biopharmaceutical Co., Ltd., Bohus BioTech AB, Boston Children’s Hospital, Brill Pharma, Calista Therapeutics, Inc., Can-Fite, BioPharma Ltd., Essex Bio-Technology Limited, Esteve, Eupraxia Pharmaceuticals Inc., Europharm Laboratoires Co. Ltd., Evonik Corporation, Exonate, EyeGate Pharmaceuticals, Inc., EyeGene, Inc., EyeTechCare SA, Eye Therapies LLC, Eyevensys SA, La Fundación General de la Universidad de Valladolid FGUVa, Galecto Biotech AB, Genable Technologies Ltd., Genentech, Inc., Gene Signal International SA, GenSight Biologics, Genzyme® Corporation, GlaxoSmithKline plc, GrayBug® LLC, Griffin Discoveries BV, G-treeBNT Co., Ltd., HanAll BioPharma Co. Ltd., Hanlim Pharmaceuticals Inc., Harmonic Pharma, Healios KK, Hemera, Biosciences, Inc., Herantis Pharma plc, High Point Pharmaceuticals, LLC (formerly TransTech Pharma, Inc.), Horus Pharma, Hubei Kangzheng Pharmaceutical Co., Ltd. and more.
Explore other reports by CHI Healthtech Market:
ReportsnReports.com is an online market research reports library of 500,000+ reports and in-depth studies of 5000+ micro markets. ReportsnReports.com offers research studies on agriculture, energy and power, automotive, Semiconductor and Electronics, Manufacturing & Construction, chemicals, environment, medical devices, healthcare, food and beverages, water and much more.
Company Name: ReportsnReports.com
Contact Person: Ritesh Tiwari
Email: Send Email
Phone: +1 888 391 5441
Address:UNIT No 802, Tower No. 7, SEZ, Magarpatta city, Hadapsar